IL44881A - Preparation of a blood fraction rich in albumin and alpha and beta-globulins - Google Patents
Preparation of a blood fraction rich in albumin and alpha and beta-globulinsInfo
- Publication number
- IL44881A IL44881A IL44881A IL4488174A IL44881A IL 44881 A IL44881 A IL 44881A IL 44881 A IL44881 A IL 44881A IL 4488174 A IL4488174 A IL 4488174A IL 44881 A IL44881 A IL 44881A
- Authority
- IL
- Israel
- Prior art keywords
- block copolymer
- concentration
- retained
- supernatant
- resulting precipitate
- Prior art date
Links
- 102000009027 Albumins Human genes 0.000 title claims description 10
- 108010088751 Albumins Proteins 0.000 title claims description 10
- 210000004369 blood Anatomy 0.000 title claims description 7
- 239000008280 blood Substances 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title claims description 4
- 102000006734 Beta-Globulins Human genes 0.000 title description 4
- 108010087504 Beta-Globulins Proteins 0.000 title description 4
- 102000002572 Alpha-Globulins Human genes 0.000 title 1
- 108010068307 Alpha-Globulins Proteins 0.000 title 1
- 239000002244 precipitate Substances 0.000 claims description 29
- 229920001400 block copolymer Polymers 0.000 claims description 19
- 230000000717 retained effect Effects 0.000 claims description 19
- 239000006228 supernatant Substances 0.000 claims description 17
- 239000001506 calcium phosphate Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 13
- 108010049003 Fibrinogen Proteins 0.000 claims description 9
- 102000008946 Fibrinogen Human genes 0.000 claims description 9
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 9
- 235000011010 calcium phosphates Nutrition 0.000 claims description 9
- 229940012952 fibrinogen Drugs 0.000 claims description 9
- -1 polyoxypropylene Polymers 0.000 claims description 9
- 230000002209 hydrophobic effect Effects 0.000 claims description 7
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 229920001451 polypropylene glycol Polymers 0.000 claims description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 102000018210 Recoverin Human genes 0.000 claims 1
- 108010076570 Recoverin Proteins 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 239000000725 suspension Substances 0.000 description 15
- 239000000203 mixture Substances 0.000 description 11
- 229920001983 poloxamer Polymers 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 238000002156 mixing Methods 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 6
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 6
- 239000003114 blood coagulation factor Substances 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 102000004338 Transferrin Human genes 0.000 description 5
- 108090000901 Transferrin Proteins 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000012581 transferrin Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000008351 acetate buffer Substances 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 4
- 235000019731 tricalcium phosphate Nutrition 0.000 description 4
- 229940078499 tricalcium phosphate Drugs 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108010077861 Kininogens Proteins 0.000 description 2
- 102000010631 Kininogens Human genes 0.000 description 2
- DZTHIGRZJZPRDV-LBPRGKRZSA-N N-acetyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-LBPRGKRZSA-N 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 239000010425 asbestos Substances 0.000 description 2
- 230000004531 blood pressure lowering effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000003058 plasma substitute Substances 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- 229910052895 riebeckite Inorganic materials 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 229960005480 sodium caprylate Drugs 0.000 description 2
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 102000004881 Angiotensinogen Human genes 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- 229920002012 Pluronic® F 38 Polymers 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 229940079718 acetyltryptophanate Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- XJFQCYIFOWHHFN-PLKCGDGVSA-N hypertensinogen Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 XJFQCYIFOWHHFN-PLKCGDGVSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QMHLJNFGMZBHIP-UHFFFAOYSA-N oxirane;propane-1,2-diol Chemical compound C1CO1.CC(O)CO QMHLJNFGMZBHIP-UHFFFAOYSA-N 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 229940079710 sodium acetyltryptophanate Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
- Y10S530/831—Cohn fractions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US00372362A US3850903A (en) | 1973-06-21 | 1973-06-21 | Plasma volume expander prepared from cohn iv precipitate using block copolymers of ethylene oxide and polyoxypropylene |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL44881A0 IL44881A0 (en) | 1974-07-31 |
| IL44881A true IL44881A (en) | 1977-05-31 |
Family
ID=23467819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL44881A IL44881A (en) | 1973-06-21 | 1974-05-22 | Preparation of a blood fraction rich in albumin and alpha and beta-globulins |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US3850903A (fr) |
| JP (1) | JPS5025721A (fr) |
| BE (1) | BE815922A (fr) |
| CA (1) | CA1025358A (fr) |
| DE (1) | DE2428982A1 (fr) |
| DK (1) | DK332174A (fr) |
| ES (1) | ES427385A1 (fr) |
| FR (1) | FR2234010B1 (fr) |
| GB (1) | GB1436529A (fr) |
| IL (1) | IL44881A (fr) |
| IT (1) | IT1058289B (fr) |
| ZA (1) | ZA743339B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4000121A (en) * | 1973-01-30 | 1976-12-28 | Baxter Travenol Laboratories, Inc. | Production of antisera comprising fractionating plasma or serum with an ethylene oxide-polyoxypropylene block copolymer |
| US3956259A (en) * | 1973-01-30 | 1976-05-11 | Baxter Laboratories, Inc. | Fractionation of blood using block copolymer of ethylene oxide and polyoxypropylene polymer to recover fraction suitable for organ perfusate |
| US4046877A (en) * | 1975-07-18 | 1977-09-06 | Syntex (U.S.A.) Inc. | Method of increasing immunologic competence |
| US4087415A (en) * | 1976-06-09 | 1978-05-02 | William L. Wilson | Antithrombin III |
| DE2801123C2 (de) * | 1977-01-26 | 1986-01-02 | Armour Pharma GmbH & Co KG, 3440 Eschwege | Verfahren zur Herstellung eines intravenös applizierbaren Serumeiweiß-Präparates |
| JPS53107479A (en) * | 1977-02-28 | 1978-09-19 | Green Cross Corp:The | Preparation of human lysozyme |
| JPS5822085B2 (ja) * | 1977-07-19 | 1983-05-06 | 株式会社ミドリ十字 | 静注用ガンマ・グロブリン製剤 |
| US4506018A (en) * | 1982-12-30 | 1985-03-19 | Becton, Dickinson And Company | Blood diluent |
-
1973
- 1973-06-21 US US00372362A patent/US3850903A/en not_active Expired - Lifetime
-
1974
- 1974-05-13 GB GB2105674A patent/GB1436529A/en not_active Expired
- 1974-05-22 IL IL44881A patent/IL44881A/en unknown
- 1974-05-24 ZA ZA00743339A patent/ZA743339B/xx unknown
- 1974-06-03 JP JP49062766A patent/JPS5025721A/ja active Pending
- 1974-06-04 CA CA201,590A patent/CA1025358A/fr not_active Expired
- 1974-06-05 BE BE145077A patent/BE815922A/fr unknown
- 1974-06-15 DE DE2428982A patent/DE2428982A1/de not_active Withdrawn
- 1974-06-18 ES ES427385A patent/ES427385A1/es not_active Expired
- 1974-06-20 IT IT24236/74A patent/IT1058289B/it active
- 1974-06-20 FR FR7421400A patent/FR2234010B1/fr not_active Expired
- 1974-06-20 DK DK332174A patent/DK332174A/da unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FR2234010A1 (fr) | 1975-01-17 |
| BE815922A (fr) | 1974-09-30 |
| IT1058289B (it) | 1982-04-10 |
| DK332174A (fr) | 1975-02-10 |
| FR2234010B1 (fr) | 1977-03-11 |
| AU7029074A (en) | 1976-01-08 |
| GB1436529A (en) | 1976-05-19 |
| US3850903A (en) | 1974-11-26 |
| ES427385A1 (es) | 1976-07-16 |
| DE2428982A1 (de) | 1975-01-16 |
| CA1025358A (fr) | 1978-01-31 |
| ZA743339B (en) | 1975-05-28 |
| IL44881A0 (en) | 1974-07-31 |
| JPS5025721A (fr) | 1975-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3956259A (en) | Fractionation of blood using block copolymer of ethylene oxide and polyoxypropylene polymer to recover fraction suitable for organ perfusate | |
| EP0037078B1 (fr) | Procédé de traitement par la chaleur d'une solution aqueuse contenant le facteur treize de coagulation du sang humain | |
| USRE29698E (en) | Stabilization of AHF using heparin | |
| US4073886A (en) | Blood fractionation process using block copolymers of ethylene oxide and polyoxypropylene | |
| JP3701028B2 (ja) | 高純度フォンビルブラント因子の入手方法 | |
| US4203891A (en) | Method of collecting anti-hemophilic factor VIII from blood and blood plasma using heparin or sodium heparin | |
| US3631018A (en) | Production of stable high-potency human ahf using polyethylene glycol and glycine to fractionate a cryoprecipitate of ahf concentrate | |
| US4188318A (en) | Simplified method for preparation of high yield, high purity Factor VIII concentrate | |
| US3682881A (en) | Fractionation of plasma using glycine and polyethylene glycol | |
| US3652530A (en) | Antihemophilic factor prepared from blood plasma using polyethylene glycol | |
| RU2603103C2 (ru) | Способ получения фибриногена с использованием сильной анионообменной смолы и содержащий фибриноген продукт | |
| SE459784B (sv) | Stabiliserad torr antitrombinberedning | |
| HU182554B (en) | Process for producing preparation of serum protein for intravenous application | |
| US4087415A (en) | Antithrombin III | |
| US4387092A (en) | Process for the preparation of factor VIII concentrate | |
| US3839314A (en) | Clarification of blood serum and plasma using block copolymers of ethylene oxide and polyoxypropylene | |
| JPH0348888B2 (fr) | ||
| IL44881A (en) | Preparation of a blood fraction rich in albumin and alpha and beta-globulins | |
| CA1054052A (fr) | Methode simplifiee pour la preparation d'un concentre de facteur viii hautement purifie | |
| CA1293941C (fr) | Methode pour preparer un facteur antihenophile (fah) par precipitation a froid et pour ameliorer la solubilite du fah recupere | |
| US4025500A (en) | Preparation of albumin by fractionation of blood plasma or serum | |
| EP0011739B1 (fr) | Procédé pour obtenir le facteur XIII de coagulation du sang dérivant du placenta humain | |
| US4822872A (en) | Method of purifying factor VIII | |
| EP0052874A1 (fr) | Méthode de génération de l'activité procoagulante du facteur VIII | |
| AU2002248415B8 (en) | Carboxylic Acid Such as Citric Acid for Disinfecting or Enhacing the Production of Blood Products Such as Plasma, Cryoprecipitate and/or Platelet |